全文获取类型
收费全文 | 270540篇 |
免费 | 4760篇 |
国内免费 | 226篇 |
专业分类
耳鼻咽喉 | 2544篇 |
儿科学 | 9569篇 |
妇产科学 | 5552篇 |
基础医学 | 29459篇 |
口腔科学 | 4097篇 |
临床医学 | 18110篇 |
内科学 | 52787篇 |
皮肤病学 | 3481篇 |
神经病学 | 23730篇 |
特种医学 | 10870篇 |
外国民族医学 | 2篇 |
外科学 | 40803篇 |
综合类 | 2749篇 |
一般理论 | 25篇 |
预防医学 | 28969篇 |
眼科学 | 4934篇 |
药学 | 16670篇 |
中国医学 | 943篇 |
肿瘤学 | 20232篇 |
出版年
2023年 | 554篇 |
2022年 | 424篇 |
2021年 | 1730篇 |
2020年 | 891篇 |
2019年 | 2005篇 |
2018年 | 24861篇 |
2017年 | 18962篇 |
2016年 | 21046篇 |
2015年 | 3003篇 |
2014年 | 3141篇 |
2013年 | 4509篇 |
2012年 | 13133篇 |
2011年 | 27072篇 |
2010年 | 21806篇 |
2009年 | 13783篇 |
2008年 | 24467篇 |
2007年 | 26934篇 |
2006年 | 5884篇 |
2005年 | 7559篇 |
2004年 | 8330篇 |
2003年 | 8927篇 |
2002年 | 6872篇 |
2001年 | 3420篇 |
2000年 | 3752篇 |
1999年 | 2820篇 |
1998年 | 665篇 |
1997年 | 498篇 |
1996年 | 422篇 |
1995年 | 363篇 |
1992年 | 1295篇 |
1991年 | 1248篇 |
1990年 | 1200篇 |
1989年 | 1037篇 |
1988年 | 928篇 |
1987年 | 925篇 |
1986年 | 844篇 |
1985年 | 817篇 |
1984年 | 597篇 |
1983年 | 481篇 |
1979年 | 594篇 |
1978年 | 350篇 |
1975年 | 351篇 |
1974年 | 546篇 |
1973年 | 491篇 |
1972年 | 431篇 |
1971年 | 389篇 |
1970年 | 483篇 |
1969年 | 445篇 |
1968年 | 422篇 |
1967年 | 370篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
12.
13.
14.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
15.
16.
M. Alexandra Friedman Charlotte M. Niznik Janelle R. Bolden Lynn M. Yee 《Journal of community health》2016,41(2):354-358
While peer support has been investigated in multiple clinical contexts, its application to the postpartum setting is unknown. The aim was to assess acceptability of a postpartum peer support program for women with diabetes. Observational survey-based needs assessment of forty low-income women with diabetes, receiving care at a major medical institution. Mean age and gravidity were 30.7 years and 3.15 ± 1.67 respectively. 45 % expressed interest in a “buddy.” There was no significant difference between groups desiring and not desiring this program. A majority of respondents desired telephone, text messaging, and in-person contacts (79.2, 72.1, 83.8 %), with 72.5 % of patients desiring diabetes-related activities during clinic waiting time. Many women desire a postpartum diabetes reciprocal peer program for support outside of clinician visits. Patients are receptive to educational services during their wait and outside of clinic time, a potentially valuable opportunity to share important health information. 相似文献
17.
18.
Megan L. Robbins Robert C. Wright Ana María López Karen Weihs 《Journal of psychosocial oncology》2019,37(2):160-177
AbstractObjectives: This study examined word use as an indicator of interpersonal positive reframing in daily conversations of couples coping with breast cancer and as a predictor of stress.Design: The Electronically Activated Recorder (EAR) and Linguistic Inquiry and Word Count (LIWC) were used to examine naturally occurring word use conceptually linked to positive reframing (positive emotion, negative emotion, and cognitive processing words).Sample: Fifty-two couples coping with breast cancer.Methods: Couples wore the EAR, a device participants wear, that audio-recorded over one weekend (>16,000 sound files), and completed self-reports of positive reframing (COPE) and stress (Perceived Stress Scale). LIWC, a software program, measured word use.Findings: Both partners’ word use (i.e., positive emotion and cognitive processing words) was associated with their own reported positive reframing, and spouses’ word use was also indicative of patients’ positive reframing. Results also revealed that, in general, words indicating positive reframing predicted lower levels of stress.Conclusions: Findings supported the hypothesis that partners—and particularly spouses of breast cancer patients—may assist each other’s coping by positively reframing the cancer experience and other negative experiences in conversation. 相似文献
19.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献20.